Novotech, Asia’s largest full-service biotech specialist CRO, has announced that affiliates of Singapore state-baked GIC and Temasek have agreed to acquire a significant stake in the company, with the additional capital earmarked to accelerate global growth. Existing investor TPG will also reinvest through its TPG Asia fund.
The transaction will...
Novo Holdings has had a busy week, co-leading and participating in major financing rounds across diverse areas of the life sciences industry. From cardiovascular devices and autoimmune disease treatments to fibrosis therapies and next-generation HDAC6 inhibitors, these investments reinforce Novo Holdings’ commitment to supporting pioneering companies developing transformative medical technologies.
US$120m Series E for Supira Medical – advancing next-gen cardiovascular support
Novo Holdings co-led an oversubscribed US$120m Series E for Supira Medical, a clinical-stage Shifamed portfolio company, alongside Qatar Investment Authority. Other investors include two undisclosed strategic investors, as well as...
